about
Infiltrative CardiomyopathiesDistribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosisNatural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugsAmyloid diseases of the heart: current and future therapiesAromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent ConjugateNanoliposomes protect against AL amyloid light chain protein-induced endothelial injuryConformational transitions induced by in vitro macromolecular crowding lead to the amyloidogenesis of buffalo heart cystatin.Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes.Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosiIntraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography.Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicitySyncope from dynamic left ventricular outflow tract obstruction simulating hypertrophic cardiomyopathy in a patient with primary AL-type amyloid heart diseaseSyncope in cardiac amyloidosis and chronic ischemic heart disease: A case reportImplantable cardioverter defibrillators in patients with cardiac amyloidosis.A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow upFamilial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case reportCardiac amyloidosis responding to bortezomib: case report and review of literature.Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing.Myocardial Deformation in Cardiac Amyloid Light-chain Amyloidosis: Assessed with 3T Cardiovascular Magnetic Resonance Feature Tracking.Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failureSenile systemic amyloidosis: clinical features at presentation and outcome.A case of cardiac amyloidosis with diuretic-refractory pleural effusions treated with bevacizumabLysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.Impact of regional left ventricular function on outcome for patients with AL amyloidosis.Predictive value of assessing diastolic strain rate on survival in cardiac amyloidosis patients with preserved ejection fraction.Single bolus versus split dose gadolinium administration in extra-cellular volume calculation at 3 Tesla.Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycansAmyloidosis: pathogenesis and new therapeutic options.Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.Next-generation endomyocardial biopsy: the potential of confocal and super-resolution microscopy.Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteinsLight Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human CardiomyocytesDirect tissue evaluation via immunofluorescence: in the diagnosis of hereditary transthyretin cardiac amyloidosis.18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.Current perspectives on cardiac amyloidosis.Application of confocal laser scanning microscopy for the diagnosis of amyloidosis.
P2860
Q26798533-95D02B12-7854-420A-B122-10066343C36EQ26864740-5CD2F50C-2AA1-4098-8ADB-D681B0EDB13DQ27009309-55E33352-0B24-4943-B80F-337CA7A0D668Q27023836-7BEB442C-77A3-4FCF-A919-3C0872D95521Q27675997-2A446610-05D7-4464-957B-7514EAF5598CQ30355633-07520276-3C85-479E-B608-C8C950A1C42CQ30375808-D25ADBA2-89ED-4F5C-AA8D-91494735142BQ30427332-A1761A97-20A7-4AE8-B7EA-611A60353DD4Q30469018-AB6EA938-4417-4C28-97FE-DFED1D561DF5Q30483215-CF3186C4-A8AE-4166-9C57-8A122715AFFCQ30493710-86D1A37F-D5BE-474E-82F8-1F8B83704E8CQ30570936-88FF88FF-A433-47D3-BCF5-2742A2435782Q33157401-C48AAD83-00C8-4B72-85F8-52F6AAE405A5Q33160234-597050E5-095B-4776-A4FC-EC658F4FADBAQ33162514-0EA1917B-F1B0-44E3-9A92-AEEFDFEF4253Q33165133-293350D6-9050-42C9-91DB-D661D68F6E21Q33304297-36596B42-0E54-4B1B-8F23-06DA21DE1C57Q33439299-56DBA06F-D34A-481E-A947-F9307793A8C0Q33580469-4F0A1C28-BD59-4DC4-8A02-E5410CC24A60Q33654026-3BF36360-621F-4E26-8CBC-5E52A51F4458Q33769385-2028F039-D317-4867-8F03-BE3C117B27B1Q33812497-640270B3-17A7-4CF6-943B-4C5652CE24AFQ33832106-3A79BE52-9FF4-4412-82D6-8E40C3B2BC66Q34240595-6F02FCB9-2E3A-414A-869D-93E5049D551FQ34340740-9D45B88D-E751-442E-96DE-63D3879507F3Q34512589-F7C6987E-6841-4035-B56E-75E3C395FE9FQ34542702-EB572EF1-3FCE-47DC-B5B9-92F5E6EEB12DQ34631654-0B20C4F8-6D11-4D17-AEAD-379B00B13979Q34776977-C4B26DC9-0DC8-4722-90BE-DCC91BFA44F3Q35030258-5EB4C5B6-FEA9-4529-9118-720A358526F4Q35103966-5981678F-B8F1-4FB0-A2EB-B62AC8F59732Q35111771-381E0B24-3A5F-42E2-BAFA-9631516CE0C4Q35215830-ED7BD9B4-DF4F-4F77-852A-5276EEF52E97Q35223076-6E896CF7-961A-4E3E-9681-06AA9AC3A335Q35601377-F70AB14B-2B6F-4625-85D2-01B632FD0355Q35783283-7233B9A4-E47E-4A88-AF09-74C0C50A43B2Q35820083-5FD63297-8F1E-4EF4-8953-964DDEF445CFQ35949385-2AA3FA57-46C8-4574-A0B2-9ADD19DEF2B6Q35964900-E9D5CD90-2426-4C68-A5A3-B51662D4E1B7Q36285865-0FD016B8-BDDA-46AD-8929-392E8329EC30
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Diagnosis and management of the cardiac amyloidoses.
@ast
Diagnosis and management of the cardiac amyloidoses.
@en
Diagnosis and management of the cardiac amyloidoses.
@nl
type
label
Diagnosis and management of the cardiac amyloidoses.
@ast
Diagnosis and management of the cardiac amyloidoses.
@en
Diagnosis and management of the cardiac amyloidoses.
@nl
prefLabel
Diagnosis and management of the cardiac amyloidoses.
@ast
Diagnosis and management of the cardiac amyloidoses.
@en
Diagnosis and management of the cardiac amyloidoses.
@nl
P1433
P1476
Diagnosis and management of the cardiac amyloidoses.
@en
P2093
Rodney H Falk
P304
P356
10.1161/CIRCULATIONAHA.104.489187
P407
P577
2005-09-01T00:00:00Z